Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Epogen Counterfeits: Amgen Not Liable For Drug Out Of Its Control, Court Says

Executive Summary

Amgen cannot be held responsible for diluted vials of Epogen appearing on the market because the product had left the company's control, a federal court ruled

You may also be interested in...



AstraZeneca Will Comply With The Spirit Of A Drug Import Law

AstraZeneca will not attempt to undermine a drug importation program if a law is enacted, AstraZeneca U.S. CEO David Brennan said

Anti-Counterfeiting Interim Step Should Be Paper Pedigree, PhRMA Says

Drug products should contain paper pedigrees as an interim anti-counterfeit measure, the Pharmaceutical Research & Manufacturers of America said at FDA's Oct. 15 Anti-Counterfeit Drug Initiative public meeting in Bethesda, Md

Counterfeit drugs

Serono's Serostim (somatropin) lot number (S810-1A1) found to contain counterfeit versions of the AIDS wasting drug, Serono announced May 16. GlaxoSmithKline reported two Ziagen (abacavir) bottles with counterfeit Combivir (lamivudine/zidovudine) labels in a May 10 "Dear Health Care Professional" letter. Two other Combivir labels are "suspect," the company said. Amgen reports counterfeit Epogen (epoetin alfa) vials containing diluted drug in May 8 letter. The unusual cluster of public counterfeiting reports, including Lilly's Zyprexa (1"The Pink Sheet" May 13, In Brief), may help the industry combat proposed reimportation legislation...

Topics

UsernamePublicRestriction

Register

PS044500

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel